P53 haploinsufficiency and functional abnormalities in multiple myeloma

Leukemia

Volumn 28, Issue 10, 2014, Pages 2066-2074

  Teoh, P J ^a,b   Chung, T H ^b   Sebastian, S ^c   Choo, S N ^d   Yan, J ^b   Ng, S B ^d,e   Fonseca, R ^c   Chng, W J ^a,b,d  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c MAYO CLINIC   (United States)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

NUTLIN 3; PROTEIN P53; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL DEATH; CELL POPULATION; CELL VIABILITY; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA METHYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ALLELE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 17; GENE DELETION; GENE SILENCING; GENETICS; METABOLISM; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ALLELES; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 17; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; GENE DELETION; GENE SILENCING; GENES, P53; HAPLOINSUFFICIENCY; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921800192     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.102     Document Type: Article

References (50)

1. Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609-3617
2. Yuregir OO, Sahin FI, Yilmaz Z, Kizilkilic E, Karakus S, Ozdogu H. Fluorescent in situ hybridization studies in multiple myeloma. Hematology 2009; 14: 90-94
3. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 2010; 9: 937-945
4. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802-809
5. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310
6. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604
7. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21: 582-584
8. Lode L, Eveillard M, Trichet V, Soussi T, Wuilleme S, Richebourg S et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010; 95: 1973-1976
9. Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosome Cancer 2011; 50: 765-774
10. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575
11. Chen MH, Qi CXY, Saha MN, Chang H. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. Am J Clin Pathol 2012; 137: 208-212
12. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472
13. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 2012; 41: D991-D995
14. Pruitt KD, Tatusova T, Brown GR, Maglott DR. NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy. Nucleic Acids Res 2011; 40: D130-D135
15. Chmelarova M, Krepinska E, Spacek J, Laco J, Beranek M, Palicka V. Methylation in the p53 promoter in epithelial ovarian cancer. Clin Trans Oncol 2012; 15: 160-163
16. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-1035
17. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028
18. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010; 116: 2543-2553
19. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177-3188
20. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-126
21. Liu DP, Song H, Xu Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2010; 29: 949-956
22. Lynch CJ, Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 2006; 25: 3463-3470
23. Saha MN, Jiang H, Chang H. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and-independent pathways. Cancer Biol Ther 2010; 10: 567-578
24. Saha MN, Micallef J, Qiu LG, Chang H. Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol 2010; 63: 204-209
25. Xiong W, Wu XS, Starnes S, Johnson SK, Haessler J, Wang SQ et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008; 112: 4235-4246
26. Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012; 26: 2406-2413
27. Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005; 65: 4673-4682
28. Chim CS, Kwong YL, Liang R. Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clin Lymphoma Myeloma 2008; 8: 331-339
29. Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood 2013; 122: 219-226
30. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358-360
31. Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004; 127: 280-284
32. Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B et al. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer 2013; 119: 1013-1022
33. Okamoto H, Fujishima F, Nakamura Y, Zuguchi M, Miyata G, Kamei T et al. Murine double minute 2 and its association with chemoradioresistance of esophageal squamous cell carcinoma. Anticancer Res 2013; 33: 1463-1471
34. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14: 5318-5324
35. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci U SA 2006; 103: 1888-1893
36. Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem 2012; 113: 433-439
37. Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G et al. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase. Haematologica 2003; 88: 622-630
38. Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, Powles R et al. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica 2003; 88: 529-537
39. Venkatachalam S, Tyner S, Pickering C, Boley S, Recio L, French J et al. Is p53 Haploinsufficient for tumor suppression? Implications for the p53 / mouse model in carcinogenicity testing. Toxicol Pathol 2001; 29: 147-154
40. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998; 17: 4657-4667
41. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852
42. Xiong W, Zhan FH, Huang YS, Barlogie B, Shaughnessy JD. TP53 gene expression, correlated with 17p13 deletion, is a significant and independent adverse prognostic factor in multiple myeloma treated with high-dose therapy and auto-transplants. Blood 2006; 108: 3394
43. Braggio E, Maiolino A, Gouveia ME, Magalhaes R, Souto Filho JT, Garnica M et al. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol 2010; 91: 87-96
44. Gonzalez M, Mateos MV, Garcia-Sanz R, Balanzategui A, Lopez-Perez R, Chillon MC et al. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia 2000; 14: 183-187
45. Chim CS, Kwong YL, Fung TK, Liang R. Methylation profiling in multiple myeloma. Leuk Res 2004; 28: 379-385
46. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG et al. DNA methylation changes in multiple myeloma. Leukemia 2004; 18: 1687-1692
47. Hurt EM, Thomas SB, Peng B, Farrar WL. Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther 2006; 5(9): 1154-1160
48. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18: 367-381
49. Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, Treon SP et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 1997; 90: 1982-1992
50. Saha MN, Jayakar J, Chang H. Nutlin-3 and Velcade synergistically induce cell cycle arrest and apoptosis in multiple myeloma through activation of p53 pathway. Modern Pathol 2009; 22: 1287.